Apixaban with antiplatelet therapy after acute coronary syndrome.
about
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeDouble or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallelSafety of apixaban for venous thromboembolism prophylaxis: the evidence to dateApixaban and oral implicationsStroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsUpdate on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current EvidenceDifferential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatranAdjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxarAnticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decadeRivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practiceAtrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institutePharmacotherapy in the cardiac catheterization laboratory: evolution and recent developmentsUnmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxarThe new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literatureAntithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulationSpecial considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillationChoosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to KnowGuidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentA review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?Adaptive Immunity Dysregulation in Acute Coronary Syndromes: From Cellular and Molecular Basis to Clinical ImplicationsDual pathway therapy in acute coronary syndrome.Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocolDirect anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients.Independent data monitoring committees: preparing a path for the future.Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.The role of prothrombin complex concentrates in reversal of target specific anticoagulants.Recent advances in antithrombotic therapy after acute coronary syndrome.Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis.Edoxaban: an update on the new oral direct factor Xa inhibitor.Balancing antiplatelet and anticoagulant therapies in patients with cardiovascular disease.Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence.Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients.
P2860
Q24623137-2E213C21-08CD-4A74-88D2-85726836B0F8Q26741058-138505B7-71E2-4DEB-A97C-0F7F698BD607Q26764874-514B8B54-121F-4070-B7A4-F6F277B36C2EQ26780328-3E4C3924-1655-424F-935B-E3516A9678B5Q26781181-E1B390E0-9497-498D-AB90-F53008F9880BQ26782483-9A7E45D8-6C0A-43F1-BF35-47A5C40A03C3Q26799710-0365F94F-3E22-4083-8738-C81263458BC5Q26801144-07010702-02E8-4517-B544-813CABA59DEAQ26824864-7241F6BE-D2AD-471C-A7B6-7496E399DA09Q26825230-928CF1F1-82A9-4756-BA90-FE54BFF2B705Q26851235-77DB6AF4-DE91-4CAC-846C-5CAF1FF4668DQ26862694-79B93F86-7979-496B-BFCC-82097772E96DQ27016071-DF91AC75-3029-48A2-A4FC-7771A0A8BB8AQ27497485-61F838B9-3C2F-4B15-9E05-86AA01D1C451Q28072522-25F15F4C-8A5E-467C-BDDE-C8ADCC1E7E25Q28072542-739D94D0-643C-4154-A3EA-7B4A08B76878Q28074445-5F9AF310-FC6C-4EEC-87F1-D3909D3320E3Q28076077-BD7CF697-71D9-45AC-8C61-A369284FA465Q28087744-95E04E49-EEC2-4EBD-BE05-6CAE92158834Q30241848-1F61A085-6083-4558-A4E2-2DA3475C9A3BQ30252011-E64A58EF-3367-4A7E-9D08-467560C1F39EQ30490484-80826BAB-18F4-49AD-834C-98CE47DD19CDQ30595943-A597C6DE-BA29-44B3-86D9-13A39B61F90BQ30838979-68280EA7-1C97-4651-83CA-3E9CBC7AB59EQ33403263-725FAB9F-0025-480C-B14F-8871A7F8CA2DQ33582537-389EE4A2-D980-4B5C-8859-62C4CBADC0B9Q33590548-46CE32CE-9D6E-463A-90F8-6928D23F5448Q33876319-D39C543D-FA79-45E0-983D-DA5FB7415EECQ33935409-6BABF406-5DAE-4B18-9EEB-BF1DAADF60F2Q33936118-C220F989-7C5A-4326-8116-C83E0F647908Q34099930-5F91C0D8-EED4-4B56-8E59-4D2709375A85Q34331671-8B92CAB8-4813-4346-9FAF-159E5D73155AQ34482427-90EA0B1F-3547-4777-A292-220F7F3E9C4FQ34554473-7FF71684-B2B8-4956-AA1D-CC6F1AED34DDQ34641456-FA13F121-E6F9-44A2-BAC9-5F1B278CCE3BQ34651036-49C51B40-B128-40DF-8C6E-CF69E717223AQ34651051-3B73EE32-9F7E-4903-B00C-F2F227E6D98BQ34670808-4E7C858B-7964-4C35-B4A1-C3578C94F471Q34725585-547F29AD-14BC-48EB-97C5-27793C272205Q35111496-A7C61147-AFB0-47AB-A85E-C4FFCF17029F
P2860
Apixaban with antiplatelet therapy after acute coronary syndrome.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Apixaban with antiplatelet therapy after acute coronary syndrome.
@ast
Apixaban with antiplatelet therapy after acute coronary syndrome.
@en
Apixaban with antiplatelet therapy after acute coronary syndrome.
@nl
type
label
Apixaban with antiplatelet therapy after acute coronary syndrome.
@ast
Apixaban with antiplatelet therapy after acute coronary syndrome.
@en
Apixaban with antiplatelet therapy after acute coronary syndrome.
@nl
prefLabel
Apixaban with antiplatelet therapy after acute coronary syndrome.
@ast
Apixaban with antiplatelet therapy after acute coronary syndrome.
@en
Apixaban with antiplatelet therapy after acute coronary syndrome.
@nl
P2093
P50
P356
P1476
Apixaban with antiplatelet therapy after acute coronary syndrome.
@en
P2093
APPRAISE-2 Investigators
Alexander Parkhomenko
Danny Liaw
Deepak L Bhatt
Dragos Vinereanu
Frank Cools
Freek W Verheugt
Harald Darius
Harvey White
Hisao Ogawa
P304
P356
10.1056/NEJMOA1105819
P407
P577
2011-07-24T00:00:00Z